New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
0.99
0.04
+4.21%
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 0.00% in Q3 FY26, the highest of these four quarters.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 51.9% | −480.1% | −126.2% | −123.1% |
| ROIC | 0.0% | 0.0% | 0.0% | 0.0% |
Debt
Net debt is 3.53× a year’s EBITDA. Debt is 0.00× equity.
Debt / equityNet debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 4.0× | 3.6× | 2.4× | 3.5× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
51.90% | (480.07%) | (126.19%) | (123.08%) | |
| (54.15%) | (47.68%) | (85.08%) | (85.24%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(88.64%) | (109.40%) | (326.11%) | (176.78%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.17) | (2.31) | (2.67) | (2.15) | |
Free Cash Flow |
(23.50) | (21.67) | (25.03) | (27.15) | |
| Other line items | |||||
Cash ROIC |
(45.40%) | (54.88%) | (103.65%) | (71.96%) | |
Operating CF/Net income |
1.29 | 1.40 | 0.96 | 1.02 | |
Depreciation/Fixed assets |
(2.02) | (2.39) | (2.92) | (3.75) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.17) | (2.31) | (2.67) | (2.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated Nov 17, 2026